Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib
Authors
Keywords
-
Journal
MOLECULES
Volume 25, Issue 5, Pages 1149
Publisher
MDPI AG
Online
2020-03-04
DOI
10.3390/molecules25051149
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
- (2019) A T Shaw et al. ANNALS OF ONCOLOGY
- Synthesis and Evaluation of Hydrogen Peroxide Sensitive Prodrugs of Methotrexate and Aminopterin for the Treatment of Rheumatoid Arthritis
- (2018) Jorge Peiró Cadahía et al. JOURNAL OF MEDICINAL CHEMISTRY
- SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
- (2017) Antoine Daina et al. Scientific Reports
- Proteases in cancer drug delivery
- (2016) Jennifer Vandooren et al. ADVANCED DRUG DELIVERY REVIEWS
- Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
- (2016) Roger M. Phillips CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Amine–boranes bearing borane-incompatible functionalities: application to selective amine protection and surface functionalization
- (2016) P. Veeraraghavan Ramachandran et al. CHEMICAL COMMUNICATIONS
- FDA-approved small-molecule kinase inhibitors
- (2015) Peng Wu et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Tumor-Targeting of EGFR Inhibitors by Hypoxia-Mediated Activation
- (2014) Claudia Karnthaler-Benbakka et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Aromatic Nitrogen Mustard-Based Prodrugs: Activity, Selectivity, and the Mechanism of DNA Cross-Linking
- (2014) Wenbing Chen et al. CHEMISTRY-A EUROPEAN JOURNAL
- Managing treatment–related adverse events associated with Alk inhibitors
- (2014) J.M. Rothenstein et al. Current Oncology
- FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements
- (2014) D. Kazandjian et al. ONCOLOGIST
- Molecular Docking: A Powerful Approach for Structure-Based Drug Discovery
- (2012) Xuan-Yu Meng et al. Current Computer-Aided Drug Design
- Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis
- (2011) Li-Hua Shao et al. CANCER
- LigPlot+: Multiple Ligand–Protein Interaction Diagrams for Drug Discovery
- (2011) Roman A. Laskowski et al. Journal of Chemical Information and Modeling
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- (2011) J. Jean Cui et al. JOURNAL OF MEDICINAL CHEMISTRY
- Aminoferrocene-Based Prodrugs Activated by Reactive Oxygen Species
- (2011) Helen Hagen et al. JOURNAL OF MEDICINAL CHEMISTRY
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading
- (2009) Oleg Trott et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
- (2009) Garrett M. Morris et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs
- (2008) Jian-Xin Duan et al. JOURNAL OF MEDICINAL CHEMISTRY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started